Skip to content
18 November · 06:30 UTCFollow AstraZeneca by emailFollow

AZN · Pharma and healthcare · one day

AstraZeneca (AZN): news on Wednesday 18 November 2026

News from the 24 hours to Wednesday morning, 18 November 2026.

Tone of the day

+7.0strongly positive
Relevant headlines29of 33 read
Stories15grouped by event

What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.

Why it scored this way

Coverage was mostly positive, centred on new US and EU approvals including Klygefa, a dismissed antitrust lawsuit and a Jefferies price target increase. The Indian arm's tie-up with Strand Life Sciences added mild support, while a layoff-related law firm probe and a small share dip were minor negatives.

What drove it

  • regulatory approvals
  • Soliris lawsuit dismissed
  • Indian unit partnership

Around this day

DayToneHeadlines
Thu 12 Nov+7.525
Fri 13 Nov+5.38
Sat 14 Nov+5.539
Sun 15 Nov+7.59
Mon 16 Nov+4.56
Tue 17 Nov+9.745
Wed 18 Nov+7.029

15 stories · 29 headlines · strongest first

Pharma and healthcare on 18 NovemberFTSE 100 that day
ToneWhat the article reported, and why it scored that waySource
Strand Life Sciences and AstraZeneca Pharma India sign letter of intent +3.610 headlines today · Many outlets report that Strand Life Sciences, a Reliance unit, and AstraZeneca Pharma India signed a letter of intent.
+5.8Indian shares gain after partnership announcement.Upstox (opens the article) ↗
+3.3Indian arm signs letter of intent with Reliance unit.LinkedIn (opens the article) ↗
+3.3Indian unit agrees to explore healthcare collaboration.BusinessLine (opens the article) ↗
+3.3Indian arm signs preliminary collaboration deal.Equitypandit (opens the article) ↗
+3.3Indian unit signs collaboration letter of intent.scanx.trade (opens the article) ↗
+3.3Indian arm partners on healthcare collaboration.Sahi (opens the article) ↗
+3.3Indian arm teams up with Reliance-owned genomics firm.The Financial Express (opens the article) ↗
+3.3Indian arm signs letter of intent with Reliance unit.CNBC TV18 (opens the article) ↗
+3.3Indian subsidiary explores healthcare collaboration with a partner.Business Upturn (opens the article) ↗
+3.3Indian unit signs preliminary letter of intent for collaboration.Business Upturn (opens the article) ↗
AstraZeneca wins several regulatory approvals +9.33 headlines today · 8 in all, since 17 November · Articles describe approvals AstraZeneca received for cardiovascular, cancer and rare disease treatments.
+10.0Multiple approvals across several therapy areas.Business Weekly (opens the article) ↗
+8.3New US and EU approvals secured during the week.Kalkine Media (opens the article) ↗
+7.5Two regulatory approvals in one day, with evidence comparison.Moomoo (opens the article) ↗
AstraZeneca's Klygefa approved for myasthenia gravis in US and EU +10.02 headlines today · 19 in all, since 15 November · Reports say Klygefa, a medicine for myasthenia gravis that patients inject themselves once a week, has been approved by the FDA and in the EU.
+10.0US regulator clears new weekly self-injected rare disease drug.MLQ.ai (opens the article) ↗
+9.2Approvals in US and EU for new drug; gains in focus.Traders Union (opens the article) ↗
AstraZeneca unit defeats Soliris monopolisation suit +8.32 headlines today · 4 in all, since 17 November · Reports say AstraZeneca's unit won dismissal of the Soliris antitrust lawsuit.
+8.3Antitrust lawsuit over biosimilar delays thrown out in its favour.Life Sciences IP Review (opens the article) ↗
+8.3Court dismisses antitrust claim against the company.PYMNTS.com (opens the article) ↗
AstraZeneca pipeline and market commentary +5.82 headlines today · Commentary pieces discuss AstraZeneca's pipeline momentum and setup.
+6.7Positive take on its developing drug pipeline.Kalkine Media (opens the article) ↗
+5.0Generally favourable commentary on the share setup.Kalkine Media (opens the article) ↗
Jefferies raises AstraZeneca target, keeps Buy +9.21 headline today · Jefferies lifted its AstraZeneca price target and maintained a Buy rating.
+9.2Broker keeps buy view and lifts price target.Moomoo (opens the article) ↗
FDA approves Imfinzi regimen for bladder cancer +10.01 headline today · 15 in all, since 14 November · The FDA has approved the regimen from AstraZeneca's VOLGA trial to treat muscle-invasive bladder cancer.
+9.2Regulatory clearance for bladder cancer treatment regimen.Oncodaily (opens the article) ↗
AstraZeneca shares have risen 12% over the past month +6.71 headline today · An article considers whether investors should purchase, dispose of or keep AstraZeneca shares after they rose 12% over a month.
+6.7Shares have risen strongly over the past month.Yahoo Finance (opens the article) ↗
AstraZeneca reduces its US sales workforce by 600 positions −3.01 headline today · 21 in all, since 14 November · A law firm announced a WARN Act investigation concerning AstraZeneca.
−6.7Law firm probing possible mass layoff notice issues.Strauss Borrelli PLLC (opens the article) ↗
AstraZeneca has acquired Omniose +5.01 headline today · A biotech round-up reports AstraZeneca acquired Omniose.
+5.0Acquisition of a biotech firm mentioned among sector news.European Biotechnology Magazine (opens the article) ↗
AstraZeneca marks Macclesfield campus 60th anniversary +4.21 headline today · AstraZeneca celebrated 60 years of its Macclesfield campus with a Guinness World Record attempt.
+4.2Positive site anniversary celebration with record attempt.Macclesfield Nub News (opens the article) ↗
AstraZeneca signs cloud ERP deal with SAP +2.91 headline today · 6 in all, since 15 November · SAP Cloud ERP Private is reported to be the platform AstraZeneca is migrating to.
+1.7Internal IT systems upgrade; minor operational story.Portal ERP (opens the article) ↗
AstraZeneca explains HER2 biomarker +1.71 headline today · AstraZeneca published an explainer on the HER2 biomarker.
+1.7Company-published educational piece on cancer biomarker.AstraZeneca (opens the article) ↗
AstraZeneca shares trade below Xetra close −1.71 headline today · A report notes AstraZeneca shares trading below their Xetra close.
−1.7Small share price dip versus prior German close.AD HOC NEWS (opens the article) ↗
AstraZeneca Pharma India asks shareholders to approve a new independent director 0.01 headline today · AstraZeneca Pharma India is seeking shareholder approval for a new independent director.
0.0Routine governance matter at Indian subsidiary.scanx.trade (opens the article) ↗

Each article has its own score. The lines are our own summary; follow the source link to read the article itself.

Follow by email

A short, free morning email on how the news treated AstraZeneca: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.

How it works. Every morning an AI model reads the UK business news about each FTSE 100 company and scores how good or bad it is for the company, from −10 to +10. Pages update by about 07:45 UK time.

Not investment advice. MarketFrame rates the tone of news coverage. It is general information, not a recommendation to buy or sell anything. The scores are not share-price data or forecasts: a good score doesn't mean a share will rise, and a bad one doesn't mean it will fall.

Data to 06:30 UTC, 18 November · 867 headlines · 94 companiesMade by Adapt Progress Evolve Limited, a UK company · Privacy · Terms · Who we are · RSS · API · llms.txt